Parvovirus B19 profiles in patients presenting with acute myocarditis and chronic dilated cardiomyopathy

Medical Science Monitor

Volumn 14, Issue 12, 2008, Pages

  Escher, Felicitas ^a   Modrow, Susanne ^b   Sabi, Titus ^a   Kühl, Uwe ^a   Lassner, Dirk ^c   Schultheiss, Heinz Peter ^a   Noutsias, Michel ^a,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c Institute of Cardiac Diagnostics and Therapy (IKDT)   (Germany)

^d UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Diagnosis; Dilated cardiomyopathy; Humoral immune response; Inflammatory cardiomyopathy; Myocarditis; Parvovirus B19

Indexed keywords

IMMUNOGLOBULIN M ANTIBODY; VIRUS DNA;

ACUTE DISEASE; ADULT; ANTIBODY DETECTION; ARTICLE; CHRONIC DISEASE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; FEMALE; HEART MUSCLE BIOPSY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PARVOVIRUS; POLYMERASE CHAIN REACTION; VIRUS DETECTION; VIRUS GENOME; VIRUS INFECTION; VIRUS MYOCARDITIS;

ACUTE DISEASE; ADULT; ANTIBODIES, VIRAL; CARDIOMYOPATHY, DILATED; CASE-CONTROL STUDIES; CHRONIC DISEASE; DNA, VIRAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDITIS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES;

EID: 46449096364     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Liu,PP, Mason JW: Advances in the understanding of myocarditis. Circulation, 2001; 104: 1076-82
2. D'Ambrosio A, Patti G, Manzoli A et al: The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart, 2001; 85: 499-504
3. Elliott P, Andersson B, Arbustini E et al: Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J, 2008; 29: 270-76
4. Kuhl U, Pauschinger M, Bock T et al: Parvovirus B19 infection mimicking acute myocardial infarction. Circulation, 2003; 108: 945-50
5. Kuhl U, Pauschinger M, Noutsias M et al: High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation, 2005; 111: 887-93
6. Mahrholdt H, Wagner A, Deluigi CC et al: Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation, 2006; 114: 1581-90
7. Gutberlet M, Spors B, Thoma T et al: Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence. Radiology, 2008; 246: 401-9
8. Pankuweit S, Moll R, Baandrup U et al: Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol, 2003; 34: 497-503
9. Kuhl U, Pauschinger M, Seeberg B et al: Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation, 2005; 112: 1965-70
10. Escher F, U Kuhl, Sabi T et al: Immunohistological Detection of Parvovirus B19 Capsid Proteins in Endomyocardial Biopsies from Dilated Cardiomyopathy Patients. Med Sci Monit, 2008; 14(6): CR333-38
11. Noutsias M, Seeberg B, Schultheiss HP, Kuhl U: Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. Circulation, 1999; 99: 2124-31
12. Angelini A, Calzolari V, Calabrese F et al: Myocarditis mimicking acute myocardial infarction: role of endomyocardial biopsy in the differential diagnosis. Heart, 2000; 84: 245-50
13. Noutsias M, Pauschinger M, Schultheiss HP, Kuhl U: Advances in the immunohistological diagnosis of inflammatory cardiomyopathy. Eur Heart J, 2002; Suppl. 4: I54-62
14. Mahrholdt H, Goedecke C, Wagner A et al: Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation, 2004; 109: 1250-58
15. Noutsias M, Pauschinger M, Ostermann K et al: Digital image analysis system for the quantification of infiltrates and cell adhesion molecules in inflammatory cardiomyopathy. Med Sci Monit, 2002; 8(5): MT59-71
16. Noutsias M, Pauschinger M, Schultheiss K, Kühl U: Phenotypic characterization of infiltrates in dilated cardiomyopathy - diagnostic significance of T-lymphocytes and macrophages in inflammatory cardiomyopathy. Med Sci Monit, 2002; 8(7): CR478-87
17. Noutsias M, Pauschinger M, Schultheiss HP, Kühl U: Cytotoxic perforin+ and TIA-1+ infiltrates are associated with cell adhesion molecule expression in dilated cardiomyopathy. Eur J Heart Fail, 2003; 5: 469-79
18. Kurtzman GJ, Cohen BJ, Field AM et al: Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest, 1989; 84: 1114-23
19. Cossart YE, Field AM, Cant B, Widdows D: Parvovirus-like particles in human sera. Lancet, 1975; 1: 72-73
20. Young NS, Brown KE: Parvovirus B19. N Engl J Med, 2004; 350: 586-97
21. Cassinotti P, Burtonboy G, Fopp M, Siegl G: Evidence for persistence of human parvovirus B19 DNA in bone marrow. J Med Virol, 1997; 53: 229-32
22. Von Landenberg P, Lehmann HW, Knoll A et al: Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum, 2003; 48: 1939-47
23. Lehmann HW, Knoll A, Kuster RM, Modrow S: Frequent infection with a viral pathogen, parvovirus B19, in rheumatic diseases of childhood. Arthritis Rheum, 2003; 48: 1631-38
24. Lehmann HW, Kuhner L, Beckenlehner K et al: Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence. J Clin Virol, 2002; 25: 135-43
25. von Poblotzki A, Hemauer A, Gigler A et al: Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implications for pathogenesis. J Infect Dis, 1995; 172: 1356-59
26. von Poblotzki A, Gigler A, Lang B et al: Antibodies to parvovirus B19 NS-1 protein in infected individuals. J Gen Virol, 1995; 76(Pt 3): 519-27
27. Kerr JR, Cunniffe VS: Antibodies to parvovirus B19 non-structural protein are associated with chronic but not acute arthritis following B19 infection. Rheumatology (Oxford), 2000; 39: 903-8
28. Franssila R, Soderlund M, Brown CS et al: IgG subclass response to human parvovirus B19 infection. Clin Diagn Virol, 1996; 6: 41-49
29. Soderlund M, Brown CS, Spaan WJ et al: Epitope type-specific IgG responses to capsid proteins VP1 and VP2 of human parvovirus B19. J Infect Dis, 1995; 172: 1431-36
30. Modrow S, Dorsch S: Antibody responses in parvovirus B19 infected patients. Pathol Biol (Paris), 2002; 50: 326-31
31. Pfrepper KI, Enders M, Motz M: Human parvovirus B19 serology and avidity using a combination of recombinant antigens enables a differentiated picture of the current state of infection. J Vet Med B Infect Dis Vet Public Health, 2005; 52: 362-65
32. Baughman KL: Diagnosis of myocarditis: death of Dallas criteria. Circulation, 2006; 113: 593-95
33. Noutsias M, Pauschinger M, Poller WC et al: Immunomodulatory treatment strategies in inflammatory cardiomyopathy: current status and future perspectives. Expert Rev Cardiovasc Ther, 2004; 2: 37-51
34. De Cobelli F, Pieroni M, Esposito A et al: Delayed gadolinium-enhanced cardiac magnetic resonance in patients with chronic myocarditis presenting with heart failure or recurrent arrhythmias. J Am Coll Cardiol, 2006; 47: 1649-54
35. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C et al: Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation, 2001; 104: 39-45
36. Modrow S: Parvovirus B19: the causative agent of dilated cardiomyopathy or a harmless passenger of the human myocard? Ernst Schering Res Found Workshop, 2006; 63-82
37. Hauck AJ, Kearney DL, Edwards WD: Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc, 1989; 64: 1235-45
38. Bultmann BD, Klingel K, Sotlar K et al: Parvovirus B19: a pathogen responsible for more than hematologic disorders. Virchows Arch, 2003; 442: 8-17
39. Moffatt S, Yaegashi N, Tada K et al: Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol, 1998; 72: 3018-28
40. Lehmann HW, von Landenberg P, Modrow S: Parvovirus B19 infection and autoimmune disease. Autoimmun Rev, 2003; 2: 218-23
41. Hemauer A, Gigler A, Searle K et al: Seroprevalence of parvovirus B19 NS1-specific IgG in B19-infected and uninfected individuals and in infected pregnant women. J Med Virol, 2000; 60: 48-55
42. Streitz, M, Noutsias M, Volkmer R et al: NS1 specific CD8+ T-cells with effector function and TRBV11 dominance in a patient with parvovirus B19 associated inflammatory cardiomyopathy. PLoS ONE, 2008; 3: e2361
43. Noutsias M, Rohde M, Block A et al: Preamplification techniques for real-time RT-PCR analyses of endomyocardial biopsies. BMC Mol Biol, 2008; 9: 3
44. Lindner J, Noutsias M, Lassner D et al: Adaptive immune responses against parvovirus B19 in patients with myocardial disease. J Clin Virol, 2008; (in press)
45. Kuhl U, Pauschinger M, Schwimmbeck PL et al: Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation, 2003; 107: 279398
46. Kuhl U, Pauschinger M, Poller W, Schultheiss HP: Anti-viral treatment in patients with virus-induced cardiomyopathy. Ernst Schering Res Found Workshop, 2006: 323-42